Subscribe To

Price Alert Latest News Economic Calendar News

CRIS / Curis Plummets To 52-Week Low After FDA Clinical Hold On Blood Cancer Trial

The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a study in relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The TakeAim Leukemia study is evaluating emavusertib (CA-4948. Read More

Demo Live Account See Partner Details

Content Topics

Curis

Plummets

52 Week

After

Clinical

Hold

Blood

Cancer

52 week

Stock

CRIS

Posted: Apr 4 2022, 09:10

Author Name: Benzinga

CRIS News

By PRNewsWire
September 6, 2023

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an ora

By Zacks Investment Research
August 3, 2023

Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a y

By PRNewsWire
July 27, 2023

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an ora

By Seeking Alpha
March 13, 2023

Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Ja

By Zacks Investment Research
March 13, 2023

Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clue

By PRNewsWire
March 8, 2023

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeu

By PRNewsWire
March 2, 2023

Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023

LEXINGTON, Mass. , March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeu

By PRNewsWire
December 5, 2022

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 a

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.